Skip to Main Content

For medical devices in the Breakthrough Devices Program, 2022 has been a breakout year.

The Food and Drug Administration is on track to top its previous records, offering expedited regulatory consideration — and if medical device companies have their way, a streamlined path to insurance coverage — to dozens of novel tools.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment